Poly (Adp-Ribose) Polymerase-1 (PARP-1) Is a Good Prognostic Marker for Pancreatic/Periampullary Cancers

Author:

Yim Kwangil1,Seo Kyung Jin1,Abdul-Ghafar Jamshid1,Alam Mohammad Rizwan1,Paik Kwang Yeol2,Chong Yosep1,Shin Ok Ran1

Affiliation:

1. Hospital Pathology

2. Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Abstract

Background Periampullary cancer (PAC) is highly aggressive with no effective adjuvant therapy or prognostic markers. Recently, poly (ADP-ribose) polymerase-1 (PARP-1) has emerged as a target in solid cancers, and its relationship with epithelial-mesenchymal transition (EMT) has been observed. However, the relationship between PARP-1 and EMT in PAC has not explored well. Materials and Methods We assessed the prognostic significance of PARP-1 in 190 PACs patients and correlated it with EMT markers, including FGF8, FGFR4, MMP2, MMP3, Snail, and ZEB1. Immunohistochemistry for PARP-1 and EMT markers was performed using a tissue microarray. Results PARP-1 and FGF8 expression were associated with better survival unlike other solid cancers (P = 0.006 and P = 0.003), and MMP3 and ZEB1 expression were associated with poor prognosis in multivariate and survival analyses (P = 0.009 and P < 0.001). In addition, PARP-1 is related negatively to Snail but not related with other EMT markers, implying an independent mechanism between PARP-1 and EMT in PACs. PARP-1 and FGF8 are independent good survival markers in PACs unlike other solid cancers. Conclusions PARP-1 and FGF8 in PACs could not be related to the EMT pathway but must be rather understood in light of similar cancer-protective roles. Further studies are required on EMT-associated immune markers in PACs.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference57 articles.

1. Annual Report to the Nation on the Status of Cancer, 1975–2014, featuring survival;J Natl Cancer Inst,2017

2. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;N Engl J Med,2013

3. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;N Engl J Med,2011

4. Epithelial-mesenchymal transition in pancreatic cancer: a review;Biomed Res Int,2017

5. Olaparib in the treatment of ovarian cancer;Future Oncol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3